Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.amjms.2016.12.013

http://scihub22266oqcxt.onion/10.1016/j.amjms.2016.12.013
suck pdf from google scholar
C5341697!5341697 !28262205
unlimited free pdf from europmc28262205
    free
PDF from PMC    free
html from PMC    free

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28262205 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi


Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28262205 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117
pmid28262205
      Am+J+Med+Sci 2017 ; 353 (3 ): 207-215
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Characterization of Mast Cell Activation Syndrome #MMPMID28262205
  • Afrin LB ; Self S ; Menk J ; Lazarchick J
  • Am J Med Sci 2017[Mar]; 353 (3 ): 207-215 PMID28262205 show ga
  • BACKGROUND: Mast cell activation syndrome (MCAS), a recently recognized nonneoplastic mast cell disease driving chronic multisystem inflammation and allergy, appears prevalent and thus important. We report the first systematic characterization of a large MCAS population. METHOD: Demographics, comorbidities, symptoms, family histories, physical examination and laboratory findings were reviewed in 298 retrospective and 115 prospective patients with MCAS. Blood samples from prospective subjects were examined by flow cytometry for clonal mast cell disease and tested for cytokines potentially driving the monocytosis frequent in MCAS. RESULTS: Demographically, white females dominated. Median ages at symptom onset and diagnosis were 9 and 49 years, respectively (range: 0-88 and 16-92, respectively) and median time from symptom onset to diagnosis was 30 years (range: 1-85). Median numbers of comorbidities, symptoms, and family medical issues were 11, 20, and 4, respectively (range: 1-66, 2-84, and 0-33, respectively). Gastroesophageal reflux, fatigue and dermatographism were the most common comorbidity, symptom and examination finding. Abnormalities in routine laboratories were common and diverse but typically modest. The most useful diagnostic markers were heparin, prostaglandin D(2), histamine and chromogranin A. Flow cytometric and cytokine assessments were unhelpful. CONCLUSIONS: Our study highlights MCAS?s morbidity burden and challenging heterogeneity. Recognition is important given good survival and treatment prospects.
  • |Adolescent [MESH]
  • |Adult [MESH]
  • |Aged [MESH]
  • |Aged, 80 and over [MESH]
  • |Biomarkers/blood [MESH]
  • |Child [MESH]
  • |Child, Preschool [MESH]
  • |Chromogranin A/blood [MESH]
  • |Female [MESH]
  • |Heparin/blood [MESH]
  • |Histamine/blood [MESH]
  • |Humans [MESH]
  • |Infant [MESH]
  • |Infant, Newborn [MESH]
  • |Male [MESH]
  • |Mastocytosis/diagnosis/*pathology [MESH]
  • |Middle Aged [MESH]
  • |Prospective Studies [MESH]
  • |Prostaglandin D2/blood [MESH]
  • |Retrospective Studies [MESH]
  • |Syndrome [MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box